Article info
PDFCommentary
CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC
- Correspondence to Professor Tim F Greten, Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI 9000 Rockville Pike, Bethesda, MD 20892, USA; tim.greten{at}nih.gov
Citation
CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC
Publication history
- Received October 10, 2017
- Revised October 14, 2017
- Accepted October 16, 2017
- First published October 24, 2017.
Online issue publication
March 06, 2019
Article Versions
- Previous version (6 March 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.